reports
- Jacob Mekhael
MaaT Pharma Secures € 37.5m tranched EIB financing
MaaT announced that it has secured a € 37.5m , 4-tranche financing from the European Investment Bank (EIB), which bears interest at 7%. In addition, MaaT will issue warrants to the EIB with each tranche. MaaT's previously communicated cash runway was into January 2026, which should now extend beyond that point following this additional funding, though we do note that disbursement of Tranches B to D is subject to operational and financing conditions, which we'd be keen to learn more about. All in...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
Vetoquinol: 2 directors
Two Directors at Vetoquinol sold/bought 9,860 shares at 75.000EUR. The significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Jacob Mekhael
MaaT Pharma Partnership with Clinigen secures MaaT013's EU commerciali...
MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...
GROUPE GUILLIN : BILAN SEMESTRIEL DE LIQUIDITE
GROUPE GUILLIN : BILAN SEMESTRIEL DE LIQUIDITE Bilan SEMESTRIEL S1 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont Au titre du contrat de liquidité confié par la société GROUPE GUILLIN à la Société de Bourse Gilbert Dupont, à la date du 30 juin 2025, les moyens suivants figuraient au compte de liquidité : Nombre d’actions : 8 355Solde en espèces : 175 955,73 € Au cours du 1er semestre 2025, il a été négocié un total de : ACHAT25 107 titres693 806,02 €1 346 transactionsVENTE23 874 titres 660 324,37 €1 152 transactions Il est rappelé que lors du bilan semestr...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Jacob Mekhael
MaaT Pharma Business update highlights upcoming priorities, final ARES...
MaaT provides a business update, which reiterated the company's progress with respect to its pipeline, and following the previously announced EU regulatory submission for MaaT013 in aGvHD, the company continues to search for a commercialisation partner in Europe ahead of a potential approval in 2H26. Timeline for MaaT013 US trial launch shifts to 2026 (from 4Q25) to focus resources on the European opportunity. Looking ahead, data updates for MaaT013 in aGvHD (final results incl. 12-month OS), as...
- Jacob Mekhael
MaaT Pharma Updated MaaT013 aGvHD EAP data at EHA shows consistent out...
MaaT reported updated early access program (EAP) results for MaaT013 (microbiome therapy, enema formulation) in aGvHD at EHA, being held 12-15 June. The data, which was previously shared in the abstract last month, shows that the response rates and overall survival observed in the steroid refractory and ruxulitinib resistant subset of patients (n=70) are in line with what was observed in the phase 3 ARES trial. In our view, this points to the consistency of outcomes with MaaT013 in this patient ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
GROUPE GUILLIN : ELIGIBILITE AU PEA-PME
GROUPE GUILLIN : ELIGIBILITE AU PEA-PME GROUPE GUILLIN Communiqué de presseOrnans, le 3 juin 2025 GROUPE GUILLIN CONFIRME SON ELIGIBILITE AU DISPOSITIF PEA-PME AU TITRE DE SON EXERCICE CLOS LE 31 DECEMBRE 2024 Groupe Guillin, spécialiste européen des solutions d’emballage alimentaire et matériels associés, confirme au titre de son exercice clos le 31 décembre 2024 son éligibilité au PEA-PME conformément aux dispositions de l’article L.221-32-2 du Code monétaire et financier, à savoir une capitalisation boursière inférieure à deux milliards d’euros. En conséquence, les actions Groupe Gui...
- Jacob Mekhael
MaaT Pharma Completes EU regulatory submission for MaaT013 in aGvHD
MaaT announced the submission of the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013 (microbiome therapy, enema formulation) in aGvHD under the brand name Xervyteg. Potential approval could be granted in 2H26, and MaaT is actively exploring strategic partnerships to commercialise MaaT013 in Europe. We believe the solid phase 3 results and good uptake in the early access program will be supportive of MaaT013's commercial launch ...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
GROUPE GUILLIN : MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES A L'AG...
GROUPE GUILLIN : MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES A L'AGM GROUPE GUILLIN ASSEMBLEE GENERALE MIXTE DU 13 JUIN 2025 Modalités de mise à disposition ou de consultation des documentspréparatoires à l’Assemblée Générale Mixte Les actionnaires de la société GROUPE GUILLIN sont informés qu’ils sont convoqués en Assemblée Générale Mixte, le vendredi 13 juin 2025 à 9 heures 30 à PARIS LA DEFENSE (92053), Châteauform du CNIT, 2 Place de la Défense. L’avis préalable à cette Assemblée comprenant l’ordre du jour ainsi que le texte des résolutions qui seront proposées au vote des action...
- Jacob Mekhael
EHA abstracts Autolus, Galapagos, MaaT
The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...
GROUPE GUILLIN : AVIS DE CONVOCATION A L'AGM DU 13 JUIN 2025
GROUPE GUILLIN : AVIS DE CONVOCATION A L'AGM DU 13 JUIN 2025 GROUPE GUILLINSociété Anonyme au capital de 11 487 825 eurosSiège social : Zone Industrielle - Avenue du Maréchal de Lattre de Tassigny 25290 Ornans349 846 303 RCS Besançon(la « Société ») AVIS DE CONVOCATION A L’ASSEMBLEE GENERALE MIXTE DU 13 JUIN 2025 Les actionnaires de la Société sont informés qu’ils seront réunis en Assemblée Générale Mixte le 13 juin 2025 à 9 heures 30 à Paris la Défense (92053), Châteauform du CNIT, 2 Place de la Défense, à l’effet de statuer sur l’ordre du jour ci-après : ORDRE DU JOUR De la compétenc...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
MaaT Pharma 1Q25 reiterates pipeline timelines, cash runway into Octob...
MaaT reported 1Q25 results with revenues of € 1.1m (1Q24 € 0.8m), and a cash position of € 24.4m (YE24: € 20.2m), which provides a cash runway into October 2025. Pipeline timelines were reiterated and we look forward to phase 2 data for MaaT013 in combination with immune checkpoint inhibitors in metastatic melanoma in 2H25, and hope to learn more about the company's progress with respect to partnering discussions for MaaT013 in aGvHD in Europe as we approach MAA submission in June 2025. We reite...
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Jacob Mekhael
MaaT Pharma FIRST LOOK: MaaT033 slows disease progression in phase 1 A...
MaaT reported additional results from the exploratory single arm phase 1b trial of MaaT033 in ALS, and we view the slower disease progression observed with MaaT033 as encouraging, though we also note the small patient numbers and single arm nature of the trial. ALS is a difficult condition, where many drugs have failed to show slowing of disease progression. As such, MaaT033's early results are promising, and the company is seeking partners focussed on ALS to progress this program. We reiterate ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.